Found: 12
Select item for more details and to access through your institution.
Drug survival, effectiveness, and safety of brodalumab for moderate‐to‐severe psoriasis up to 3 years.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 7, p. 922, doi. 10.1111/ijd.17038
- By:
- Publication type:
- Article
Time trend analysis (2009-2016) of antimicrobial susceptibility in Neisseria gonorrhoeae isolated in Italy following the introduction of the combined antimicrobial therapy.
- Published in:
- PLoS ONE, 2017, v. 12, n. 12, p. 1, doi. 10.1371/journal.pone.0189484
- By:
- Publication type:
- Article
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 12, p. 2187, doi. 10.1111/exd.14731
- By:
- Publication type:
- Article
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 9, p. 1591, doi. 10.1111/exd.14874
- By:
- Publication type:
- Article
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study.
- Published in:
- Dermatologic Therapy, 2023, p. 1, doi. 10.1155/2023/1793535
- By:
- Publication type:
- Article
Tildrakizumab in real‐life shows good efficacy in moderate‐to‐severe psoriasis regardless of previous use of biologic drugs and joint involvement.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 11, p. 1, doi. 10.1111/dth.15818
- By:
- Publication type:
- Article
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 1, p. 34, doi. 10.1111/ddg.15251_g
- By:
- Publication type:
- Article
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 1, p. 34, doi. 10.1111/ddg.15251
- By:
- Publication type:
- Article
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 24, p. 7503, doi. 10.3390/jcm12247503
- By:
- Publication type:
- Article
Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre.
- Published in:
- Australasian Journal of Dermatology, 2021, v. 62, n. 3, p. e431, doi. 10.1111/ajd.13632
- By:
- Publication type:
- Article
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.
- Published in:
- Journal of Personalized Medicine, 2024, v. 14, n. 7, p. 718, doi. 10.3390/jpm14070718
- By:
- Publication type:
- Article
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 4, p. 379, doi. 10.1093/ced/llac098
- By:
- Publication type:
- Article